Bluebird bio Inc (NASDAQ:BLUE) has a beta value of 0.33 and has seen 1.24 million shares traded in the last trading session. The BLUE stock price is -475.45% off its 52-week high price of $28.60 and 35.61% above the 52-week low of $3.20.
The consensus among analysts is that Bluebird bio Inc (BLUE) is Buy stock at the moment, with a recommendation rating of 2.00. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 4 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.91.
Bluebird bio Inc (NASDAQ:BLUE) trade information
Over the past 30 days, the shares of Bluebird bio Inc (NASDAQ:BLUE) have changed 21.81%.
Wall Street analysts have a consensus price target for the stock at $12.5, which means that the shares’ value could jump 60.24% from current levels. The projected low price target is $5.0 while the price target rests at a high of $25.0. In that case, then, we find that the current price level is -403.02% off the targeted high while a plunge would see the stock gain -0.6% from current levels.
Bluebird bio Inc (BLUE) estimates and forecasts
The company’s shares have lost -31.30% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 171.07%.
3 analysts offering their estimates for the company have set an average revenue estimate of 45.6M for the current quarter. 2 have an estimated revenue figure of 68.3M for the next ending quarter. Year-ago sales stood 16.1M and 10.61M respectively for this quarter and the next, and analysts expect sales will grow by 183.23% for the current quarter and 171.07% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 38.66% over the past 5 years. Earnings growth for 2025 is a modest 41.48% while over the next 5 years, the company’s earnings are expected to increase by 34.78%.
BLUE Dividends
Bluebird bio Inc is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Bluebird bio Inc (NASDAQ:BLUE)’s Major holders
The top two institutional holders are BLACKROCK INC. with over 15.44 million shares worth more than $15.2 million. As of 2024-06-30, BLACKROCK INC. held 0.3986% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 10.3 million shares as of 2024-06-30. The firm’s total holdings are worth over $10.14 million and represent 0.2659% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Mar 31, 2025 , the former fund manager holds about 2.99% shares in the company for having 293.12 shares of worth $1.46 million while later fund manager owns 259.18 shares of worth $1.29 million as of Mar 31, 2025 , which makes it owner of about 2.65% of company’s outstanding stock.
